There’s a new report out today entitled “Best and worst states for doctors” … but don’t get the wrong idea. This report is absolutely not about the states where you will find the best doctors. It is about the states (more…)
For the last few weeks, certain corners of the internet have been abuzz over the idea that Google’s algorithms may begin to take the factualness of web pages into consideration. This metric is called the Knowledge-Based Trust score. For the moment, Google is merely doing (more…)
The value and the cost of drugs used in the treatment of cancer are back in the news again this week … and not just here in the USA, either.
In the most recent issue of the Mayo Clinic Proceedings, Drs. Hagop Kantarjian and Vincent Rajkumar (more…)
While deep diving into the capacity changes underway in the specialty pharmaceutical sector of health care and at the same time trying to wrap my arms around the onslaught of activity and excitement revving up in the wings about biosimilars soon coming to market, I (more…)
On March 6, 2015, the U.S. Food and Drug Administration (FDA) approved the first “biosimilar” to be given marketing approval in the USA (although a relatively small number of biosimilars have been available in Europe since 2006). This approval had been recommended by an FDA (more…)
As stated in a post written by Mike Scott titled “New Orphan Drug Applications, Approvals Shattering Records”, a record number of orphan drug designations were approved by the FDA in 2014. The shift is clear: pharmaceutical and biotechnology companies are focusing more and (more…)
It’s time for the pharmaceutical industry to put a more deliberate focus on the customer, not just the brand. On Day 3 of ePharma 2015, “Patient-Centricity” was a common theme. But how do we make a shift like this, and how do we do it (more…)